EMW has served as a scientific consultant to Axsome Therapeutics, DayZz, Ensodata, Eisai, Idorsia, Merck, Nox Health, Primasun, Purdue, and ResMed and is an equity shareholder in WellTap. This study was funded by grants R01NS105503, R01NS105503-04S1, and R03NS088014 from the National Institute of Neurological Disorders and Stroke, W81XWH-24-CCCRP1 from the U. S. Air Force, HR001122s0043-RITMO-PA-006 from the Defense Advanced Research Projects Agency, and MTEC-20-13-IMAS-006 from the U. S.